Radiation Therapy and Chemotherapy Before and After Surgery in Treating Patients With Esophageal Cancer

Part of paid clinical trials in Denver, Colorado.

Sponsor
Eastern Cooperative Oncology Group
Study ID
NCT00033657
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • cisplatin — DRUG
    Days 1 - 35 : Cisplatin 30 mg/m² days 1, 8, 15, 22, 29 Days 63 - 77 : cisplatin 30 mg/m² and irinotecan 65 mg/m² days 1 and 8 of three 3-week cycles
  • irinotecan hydrochloride — DRUG
    Days 1 - 35 : Irinotecan 65 mg/m² days 1, 8, 22, 29 Days 63 - 77 : irinotecan 65 mg/m² days 1 and 8 of three 3-week cycles
  • paclitaxel — DRUG
    Days 1 - 35 : Paclitaxel 50 mg/m² (1 hr) days 1, 8, 15, 22, 29 Days 63 - 77 : paclitaxel 175 mg/m² and cisplatin 75 mg/m² day 1 of three 3-week cycles
  • conventional surgery — PROCEDURE
    The type of resection (lvor-Lewis, Transhiatal, etc.) was left to the discretion of the operating surgeon. One lymph node dissection was required.
  • radiation therapy — RADIATION
    The total dose to the prescription point was 4500 cGy given in 25 fractions. The patient was treated with one fraction per day with all fields treated per day. 180 cGy was delivered to the isocenter. If the dose to the supraclavicular fossa (SCF) was less than 4500 cGy, a localized photon or electron boost was allowed in order to increase the SCF dose to 4500 cGy, specified at 3 cm depth from the anterior skin surface.

Study Details

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy before and after surgery may kill more tumor cells. PURPOSE: Randomized phase II trial to compare the effectiveness of combining radiation therapy with two different chemotherapy regimens before and after surgery in treating patients who have esophageal cancer.

Key Dates

Start date
Aug 15, 2002
Status verified
Jun 2023
Primary completion
Sep 30, 2009
Completion
Oct 31, 2009

Study Design

Enrollment
97 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Cisplatin / Irinotecan / Radiation therapy (Arm A)
    Days 1 - 35 : Concurrent radiation therapy (RT) and Cisplatin / Irinotecan Chemotherapy. Radiotherapy 45 Gy administered at 1.8 Gy per day, 5 days a week for 5 weeks. Cisplatin 30 mg/m² days 1, 8, 22, 29. Irinotecan 65 mg/m² days 1, 8, 22, 29. Chemotherapy should begin within 24 hours of start of radiotherapy Days 63 - 77 : Surgical Resection At least 28 days after surgical resection, begin adjuvant chemotherapy: cisplatin 30 mg/m² and irinotecan 65 mg/m² days 1 and 8 of three 3-week cycles
  • Experimental: Paclitaxel / Cisplatin / Radiation therapy (Arm B)
    Days 1 - 35 : Concurrent radiation therapy (RT) and Paclitaxel/Cisplatin Chemotherapy. Radiotherapy 45 Gy administered at 1.8 Gy per day, 5 days a week for 5 weeks. Paclitaxel 50 mg/m² (1 hr) days 1, 8, 15, 22, 29. Cisplatin 30 mg/m² days 1, 8, 15, 22, 29. Chemotherapy should begin within 24 hours of start of radiotherapy. Days 63 - 77 : Surgical Resection At least 28 days after surgical resection, begin adjuvant chemotherapy: paclitaxel 175 mg/m² and cisplatin 75 mg/m² day 1 of three 3-week cycles.

Primary Outcome Measure

Pathologic Complete Response Rate [ Time Frame: approximately 1 month after completing all treatments, then every 3 months up to 2 years, every 6 months from 2-5 years of study entry and annually 6-10 years from study entry ]

Locations (23)

FacilityCityStateZIPSite coordinators
CCOP - Colorado Cancer Research Program, IncorporatedDenverColorado80224-
CCOP - Christiana Care Health ServicesNewarkDelaware19713-
Shands Cancer Center at the University of Florida Health Science CenterGainesvilleFlorida32610-100277-
Robert H. Lurie Comprehensive Cancer Center at Northwestern UniversityChicagoIllinois60611-
Veterans Affairs Medical Center - Lakeside ChicagoChicagoIllinois60611-4494-
CCOP - Carle Cancer CenterUrbanaIllinois61801-
CCOP - Iowa Oncology Research AssociationDes MoinesIowa50309-1016-
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsBaltimoreMaryland21231-
CCOP - Michigan Cancer Research ConsortiumAnn ArborMichigan48106-
Mayo Clinic Cancer CenterRochesterMinnesota55905-
CCOP - Metro-MinnesotaSaint Louis ParkMinnesota55416-
St. Joseph's HospitalSaint PaulMinnesota55102-
Cancer Institute of New Jersey at Robert Wood Johnson University HospitalNew BrunswickNew Jersey08903-
Ireland Cancer CenterClevelandOhio44106-5065-
MetroHealth's Cancer Care Center at MetroHealth Medical CenterClevelandOhio44109-
CCOP - Toledo Community HospitalToledoOhio43623-3456-
CCOP - MainLine HealthWynnewoodPennsylvania19096-
Lankenau Cancer Center at Lankenau HospitalWynnewoodPennsylvania19096-
CCOP - Sioux Community Cancer ConsortiumSioux FallsSouth Dakota57104-
CCOP - Scott and White HospitalTempleTexas76508-
CCOP - St. Vincent Hospital Cancer Center, Green BayGreen BayWisconsin54307-3453-
University of Wisconsin Comprehensive Cancer CenterMadisonWisconsin53792-0001-
CCOP - Marshfield Clinic Research FoundationMarshfieldWisconsin54449-

Find similar trials in Denver, CO

Related Studies